AssetMark’s Agios Pharmaceuticals AGIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$52.5K Buy
1,579
+262
+20% +$9.16K ﹤0.01% 1868
2026
Q2
$48.9K Hold
1,317
– – ﹤0.01% 1840
2026
Q1
$44.6K Hold
1,317
– – ﹤0.01% 1787
2025
Q4
$35.8K Buy
1,317
+362
+38% +$12.7K ﹤0.01% 1825
2025
Q3
$38.3K Hold
955
– – ﹤0.01% 1724
2025
Q2
$31.8K Buy
955
+150
+19% +$4.55K ﹤0.01% 1685
2025
Q1
$23.6K Buy
805
+250
+45% +$8.29K ﹤0.01% 1665
2024
Q4
$18.2K Hold
555
– – ﹤0.01% 1675
2024
Q3
$24.7K Hold
555
– – ﹤0.01% 1451
2024
Q2
$23.9K Hold
555
– – ﹤0.01% 1354
2024
Q1
$16.2K Buy
+555
New +$14.9K ﹤0.01% 1315

Other funds holding AGIO

AssetMark's AGIO Position: Q3 2026 in Review

AssetMark increased its Agios Pharmaceuticals (AGIO) stake by 20% in Q3 2026, buying an estimated $9.16K and bringing the position to 1,579 shares worth $52.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1868.

AssetMark first reported a position in AGIO in Q1 2024 and has held it in 11 quarters since. 181 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

  • AssetMark held 1,579 shares of Agios Pharmaceuticals worth $52.5K as of Q3 2026.
  • AssetMark bought 262 Agios Pharmaceuticals shares in Q3 2026, an estimated $9.16K.
  • Agios Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1868 holding.
  • AssetMark first reported a position in Agios Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
  • 181 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.